State-of-the-Art Paper
Definitions and Diagnosis of Pulmonary Hypertension

https://doi.org/10.1016/j.jacc.2013.10.032Get rights and content
Under an Elsevier user license
open archive

Pulmonary hypertension (PH) is defined by a mean pulmonary artery pressure ≥25 mm Hg at rest, measured during right heart catheterization. There is still insufficient evidence to add an exercise criterion to this definition. The term pulmonary arterial hypertension (PAH) describes a subpopulation of patients with PH characterized hemodynamically by the presence of pre-capillary PH including an end-expiratory pulmonary artery wedge pressure (PAWP) ≤15 mm Hg and a pulmonary vascular resistance >3 Wood units. Right heart catheterization remains essential for a diagnosis of PH or PAH. This procedure requires further standardization, including uniformity of the pressure transducer zero level at the midthoracic line, which is at the level of the left atrium. One of the most common problems in the diagnostic workup of patients with PH is the distinction between PAH and PH due to left heart failure with preserved ejection fraction (HFpEF). A normal PAWP does not rule out the presence of HFpEF. Volume or exercise challenge during right heart catheterization may be useful to unmask the presence of left heart disease, but both tools require further evaluation before their use in general practice can be recommended. Early diagnosis of PAH remains difficult, and screening programs in asymptomatic patients are feasible only in high-risk populations, particularly in patients with systemic sclerosis, for whom recent data suggest that a combination of clinical assessment and pulmonary function testing including diffusion capacity for carbon monoxide, biomarkers, and echocardiography has a higher predictive value than echocardiography alone.

Key Words

diagnosis
hemodynamics
pulmonary hypertension
right heart catheterization
screening

Abbreviations and Acronyms

CO
cardiac output
CTD
connective tissue disease
DLCO
diffusion capacity for carbon monoxide
HFpEF
heart failure with preserved ejection fraction
HPAH
heritable pulmonary arterial hypertension
IPAH
idiopathic pulmonary arterial hypertension
LVEDP
left ventricular end-diastolic pressure
NT-proBNP
N-terminal pro–B-type natriuretic peptide
PAH
pulmonary arterial hypertension
PAPm
mean pulmonary artery pressure
PAWP
pulmonary artery wedge pressure
PH
pulmonary hypertension
PVR
pulmonary vascular resistance
RHC
right heart catheterization
SSc
scleroderma
WU
Wood units

Cited by (0)

Dr. Hoeper has received speaker and/or consulting fees from Actelion, Bayer, Gilead, GlaxoSmithKline, Eli Lilly, Lung Rx, Pfizer, and Novartis. Dr. Bogaard has received speaker fees from and served on advisory boards for Pfizer and United Therapeutics. Dr. Condliffe has received speaker and/or conference travel fees from and/or served on advisory boards for Actelion, Bayer, Pfizer, GlaxoSmithKline, and Eli Lilly. Dr. Frantz has received consulting fees from Pfizer; and has received research funding from United Therapeutics. Dr. Khanna has received speaker and/or conference travel fees from and/or served on advisory boards for Actelion, Bayer, Bristol-Myers Squibb, Digna, Intermone, Gilead, Pfizer, Roche, Sanofi-Aventis, and United Therapeutics; and has received research funding from the National Institutes of Health and the Scleroderma Foundation. Dr. Kurzyna has received speaker and/or conference travel fees from and/or served on advisory boards for Bayer, AOP Orphan, Actelion, Pfizer, and GlaxoSmithKline. Dr. Langleben has received speaker and/or consulting fees from, has served on advisory boards for, and/or has been an investigator in clinical trials for Actelion, Bayer, GlaxoSmithKline, Eli Lilly, Myogen, Northern Therapeutics, Novartis, Pfizer, and United Therapeutics. Dr. Manes has received speaker fees from Actelion, Bayer, and GlaxoSmithKline. Dr. Satoh has received speaker fees from Actelion. Dr. Torres has received grant funding from GENO, Medtronic, Actelion/CoTherix, Gilead, Pfizer, United Therapeutics/Lung Rx, Eli Lilly/ICOS, Bayer, Novartis, Akaria, and ARIES; has served as a consultant (often in the role of steering committee or advisory board member) for Actelion/CoTherix, Gilead, Novartis, Pfizer, United Therapeutics/Lung Rx, GlaxoSmithKline, and Bayer; and is a speaker/advisory board member of Gilead, Actelion, United Therapeutics, Bayer, and Novartis. Dr. Wilkins has received speaker and/or consulting fees from Bayer, GlaxoSmithKline, Pfizer, and Novartis; and has received research funding from the British Heart Foundation, Wellcome Trust, and the National Institutes of Health. Dr. Badesch has received grant funding from Actelion/CoTherix, Gilead, Pfizer, United Therapeutics/Lung Rx, Eli Lilly/ICOS, Bayer, Novartis, Ikaria, and ARIES; has served as a consultant (often in the role of steering committee or advisory board member) for Actelion/CoTherix, Gilead, Pfizer, Mondo-Biotech/Mondogen, United Therapeutics/Lung Rx, GlaxoSmithKline, Eli Lilly/ICOS, Bayer, Ikaria, Reatta, and Arena; and has provided advice in a legal matter to Actelion.